Speaking of survival, I'm curious about something. Since we are moving into Phase 3, does that mean we won't receive any more updates on the patients from Phase 2? Also in Sept 2015 it was announced Stage 1 data showed that treatment with axalimogene filolisbac resulted in a 38.5 percent 12-month overall survival rate in 26 patients. So at that time 10 patients remained alive.
Then in Oct 2016 Advaxis' GOG-0265 trial showed that patients treated with the axalimogene filolisbac drug during the second stage pre-hold period experienced a 37.5% 12-month overall survival rate. Don't know how many patients there were or how many still alive.
Then in March this year ADXS reported GOG-0265 demonstrated that 38% of patients (n = 19/50) with heavily pretreated PRmCC were alive 12 months following treatment with axalimogene filolisbac. Also a durable complete response in a patient with PRmCC previously treated with chemotherapy and bevacizumab remains ongoing at 18.5 months. (which is great) And 8 patients remain alive as of January 31, 2017 (Range 12.02 – 40.6 months)
I copy and pasted much of the above. Everyone agrees these are great results but what I am wondering is are we going to continue to get updates on how many patients from this phase 2 are still alive? Also something else maybe someone who is good at understanding this stuff can explain: As stated in the press release in March this year, after 12 months there were 19 survivors (out of 50 patients), but it goes on to say that there are 8 patients who remain alive as of Jan 31, 2017 (ranging from 12.02-40.6 months). I don't understand how there can be 19 survivors in March but there were only 8 in January. All comments welcome.
